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Background: Pomegranate possesses many medicinal properties such as antioxidant, anti-inflammation and antitumor.
It has been extensively used as a folk medicine by many cultures. Pomegranate fruit has been shown to have the
inhibitory efficacy against prostate cancer and lung cancer in vitro and in vivo. It can be exploited in chemoprevention
and chemotherapy of prostate cancer. In this study we examined the anti-cancer efficacy of pomegranate fruit grown
in Taiwan against urinary bladder urothelial carcinoma (UBUC) and its mechanism of action.
Methods: Edible portion of Taiwanese pomegranate was extracted using ethanol and the anti-cancer effectiveness of
ethanol extract was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Flow cytometry
and western immunoblotting were exploited to uncover the molecular pathways underlying anti-UBUC activity
of Taiwanese pomegranate ethanol extract.
Results: This study demonstrated that Taiwanese pomegranate fruit ethanol extract (PEE) could effectively restrict
the proliferation of UBUC T24 and J82 cells. Cell cycle analyses indicated that the S phase arrest induced by PEE
treatment might be caused by an increase in cyclin A protein level and a decrease in the expression of cyclin-dependent
kinase 1. The results of western immunoblotting demonstrated that PEE treatment could not only evoke the activation
of pro-caspase-3, -8,-9 but also increase Bax/Bcl-2 ratio in T24 cells. The above observations implicated that PEE
administration might trigger the apoptosis in T24 cells through death receptor signaling and mitochondrial damage
pathway. Besides we found that PEE exposure to T24 cells could provoke intensive activation of procaspase-12 and
enhance the expressions of CHOP and Bip, endoplasmic reticulum (ER) stress marker, suggesting that ER stress might
be the cardinal apoptotic mechanism of PEE-induced inhibition of bladder cancer cell.
Conclusions: The analytical results of this study help to provide insight into the molecular mechanism of induced
bladder cancer cell apoptosis by pomegranate and to develop novel mechanism-based chemopreventive strategy for
bladder cancer.Background
Many epidemiologic and scientific evidences strongly imply
that plant-derived phytochemicals may provide a critical
clue for cancer prevention or treatment [1-5]. Pomegranate
(Punica granatum, Punicaceae) has been extensively used
as a folk medicine in many countries [6]. Edible portions
(80% of total fruit weight) of pomegranate fruit comprise* Correspondence: wutingfe@mail.stust.edu.tw
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reproduction in any medium, provided the or80% juice and 20% seed with nutritious ingredients of
crude fibers, pectin, sugars, and polyphenols [tannins
(mainly ellagitannins), flavonoids and anthocyanins] which
confer the fruit with potent antioxidant activity [7-10].
Cumulative findings have demonstrated that pomegran-
ate fruit have various anti-tumor capabilities. Anthocyanin/
ellagitannin-rich pomegranate fruit extract (PFE) prepared
from pomegranate edible portion with 70% acetone was
found to evoke the apoptotic impacts on human lung
cancer A549 cells by hampering NF-κB as well as MAP
kinase pathway (p38, PI3K/Akt, JNK and Erk) and the. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing in the G1 stage [11]. In primary lung tumor animal
model, PFE also inhibits tumor growth/progression/angio-
genesis by the suppression of NF-κB, MAP kinase pathway
and mTOR signaling pathway [12]. In addition to the influ-
ences on lung cancer, various preparations of pomegranate
were investigated on human prostate cancer. Oral feeding
of 0.1% and 0.2% (w/v) PFE significantly restricts the tumor
growth of androgen-responsive CWR22Rv1 cell in athymic
nude mice. PFE can cause G1-phase arrest of prostate
cancer PC3 cell through dwindling the expressions of
cyclins D and E and increasing the levels of cyclin-
dependent kinase-2, -4 and -6, and thus resulting in an
increase in WAF1/p21 as well as KIP1/p27 [13]. It also
provokes PC3 cell apoptosis by over-expression of proapop-
totic Bax and Bak while down-regulating anti-apoptotic
Bcl-2 as well as Bcl-XL. Other investigations on prostate
cancer found that pomegranate polyphenols, ellagitannin-
rich extract (PE) made from fruit skins standardized to
ellagitannins, can restraint prostate cancer cell caused by
chronic inflammation via suppressing NF-κB pathway,
which is well-established signaling pathway mediating the
inflammation relevant to cancer [14]. PE was also found
to thwart angiogenesis in prostate cancer through down-
regulation of hypoxia-inducible factor 1-α (HIF-1α) which
takes part in the expression of vascular endothelial growth
factor (VEGF) by transcriptional regulation [15]. A phase
II clinical study for men with rising PSA after surgery
or radiotherapy demonstrated that pomegranate juice
can statistically prolong PSA doubling time, suggesting
potential preventive efficacy of pomegranate in human
prostate cancer [16].
Bladder cancer is the most prevalent tumor of urinary
tract worldwide. Among the broad range of histological
heterogeneous tumor types that derive from the urothe-
lium lining of urinary bladder and ureters, urothelial
carcinoma is the most common which constitutes more
than 90% of bladder cancer cases in developed countries
[17]. Although the majority of urinary bladder urothelial
carcinoma (UBUC) is papillary and non- or superficially
invasive, cured most of the time by curettage, some
UBUCs develop relentless local recurrence followed by
lethal distal spreading [18,19]. Thus pomegranate may be
a potential chemopreventive source against UBUC devel-
opment and recurrence based upon the aforementioned
evidences. Nevertheless nowadays there is no literature
showing that pomegranate foils UBUC.
In this study we examine the inhibitory function of
pomegranate fruit ethanol extract (PEE) in UBUC. We
found that PEE could retard UBUC T24 and J82 cell
proliferation. The inhibitory effects might be attributed
to S-phase arrest provoked by PEE via de-regulating the
cylin A and cdc2 or cell apoptosis within T24 cell. Our
results showed that PEE could evoke T24 cell apoptosisvia mitochondrial pathway, death receptor pathway and
endothelium reticulum (ER) stress. Nevertheless, stronger
ER stress response was observed in T24 cell. Further-
more PEE-evoked ER stress might dys-regulate vasolin-
containing protein (VCP) to activate pro-caspase-12, and
thus induce the apoptosis in T24 cell.Methods
Collection and identification of plant materials
The fruits of P. granatum were field collected from a
farm land (22°41'59.3267” N, 120°30'45.1836” E) located in
a small township Jiuru, Pingtung county, southern Taiwan
from August to September, 2012. The plant specimens
were identified by Liao, G.-I. and pressed/dried for voucher
specimens (Nan-Kai Lin, STUSTG308-001 to STUSTG308-
003) deposited in the herbarium of Taiwan forestry research
Institute (TAIF), Taiwan.Preparation of pomegranate fruit ethanol extract (PEE)
Fresh pomegranate fruit was peeled and the edible
portion was squeezed with gauze. The subsequent juice
was concentrated by freeze dried with 37.5 ml juice to
produce 4.13 g of powder. The powder was first extracted
with ethylacetate (EtOAc) at a ratio of 1:3 (w/v) in 50 mL-
poly-propylene (PP) centrifugation tube with 360° rotation
for 16 hours at room temperature. After extraction, the
residue was collected with centrifugation at 10,000 × g and
the supernatant was vacuum dried. After centrifugation,
the residue was extracted with 70% ethanol as described
in EtOAc extraction. After extraction, 17 mg [yield 0.41%
(w/w)] and 2.96 g [yield 71.7% (w/w)] of the products were
obtained respectively from EtOAc and EtOH extraction of
37.5 ml juice.Cell lines
Human urinary bladder urothelial carcinoma (UBUC)
T24 cell, which is recognized as high grade and invasive,
was purchased from Bioresource Collection and Research
Center, Hsinchu, Taiwan and cultured at 37°C in McCoy's5A
[GIBCO (Life technologies), Grand Island, N.Y., U.S.A.],
supplemented with 10% (v/v) fetal bovine serum (FBS).
Human papillomavirus E7 immortalized uroepithelial cell
was kindly provided by Professor Hsiao-Sheng Liu from
department of microbiology and immunology, college of
medicine, National Cheng Kung University, Tainan, Taiwan
and maintained as described previously [20]. UBUC J82 cells
recognized as high grade was offered by Dr. Chien-Feng Li
from Department of Pathology, Chi-Mei Medical Center,
Tainan, Taiwan and maintained at 37°C in Dulbecco's
Modified Eagle Medium supplemented with 10% (v/v)
FBS (GIBCO, Grand Island, N.Y., U.S.A.).
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bromide (MTT) assay
Appropriate concentrations of PEE were added to a 96-
well plate already seeded with 5,000 human T24 cells,
6,000 human J82 cells or 3,000 human E7 cells per well.
After exposure for the indicated time duration, 20 μl of
MTT solution (Merck, Damstadt, German) (5 mg/ml
PBS) was added to each well and the plate was incu-
bated at 37°C for 4 hours. After medium removal,
200 μl of DMSO was added to each well and the plate
was gently shaken for 5 minutes. The absorbance was
determined at 540 nm. Quadruplicate wells were applied
to each concentration for a specific time period. 0.002%
(v/v) DMSO (vehicle)-treated bladder cancer cells were
employed as the control.
Cell cycle analysis of PEE-treated human T24 cells
Human T24 cells were plated onto a 6-well plate at 8 ×
105/well and cultivated overnight. Then 50 or 100 μg/ml
of PEE was added onto each well and the cells were
harvested with trypsinization at the indicated time
period. The harvested cells were incubated with 500 μl
of ice-cold 70% ethanol/well at 4°C overnight. After
ethanol treatment, the cells were washed with 1 ml ice-cold
PBS/well, re-suspended in 100 μl PBS/well and incubated
with 300 μl propidium iodide (PI) (Sigma, Saint Louis,












Figure 1 The extraction procedure of PEE and HPLC results. HPLC was
extracted sequentially by ethylacetate and 70% ethanol (supernatant, abbre
and pure ellagic acid were indicated above the panels respectively. The po
arrow and a letter.well in the dark at 37°C for 30 minutes. The stained cells
are analyzed by FACSCalibur flow cytometer (Becton
Dickinson). 0.002% (v/v) DMSO-treated human T24 cells
were used as the control and analyzed as described above.Annexin V/PI staining of PEE-exposed human T24 cells
Human T24 cells were plated onto a 6-well plate at 4 ×
105/well and cultivated overnight. Then 50 or 100 μg/ml
of PEE was added onto each well and the cells were
harvested with trypsinization at the indicated time period.
The harvested cells were washed with 1 ml ice-cold PBS/
well and re-suspended in 100 μl binding buffer/well. Then
2 μl of annexin V conjugated with FITC (Strong Biotech
Corporation, Tainan, Taiwan) plus 2 μl of PI solution
(Sigma, Saint Louis, Missouri, USA) were mixed with
the re-suspended cells and incubated in the dark on ice
for 15 minutes. After staining, the cells were analyzed
using FACSCalibur, Becton Dickinson. 0.002% (v/v)
DMSO-treated human T24 cells were utilized as the
control and analyzed as described above. As to annexin
V/PI experiments incorporated with caspase-3 Z-DEVD-
FMK inhibitor (BD Bioscience), human T24 cells were
incubated with 2 μM inhibitor for 4 hours. Then
inhibitor-pre-incubated human T24 cells were exposed
in the presence or absence of 100 μg/ml PEE for
48 hours. Apoptosis was detected as described above.Retention time Peak Retention time
29.21 min Pure punicalagin 31.74 min




underwent as described in Methods. (A) Local pomegranate juice was
viated Sup.). (B) HPLC profiles of PEE. The profiles of pure unicalagin
ssible punicalagin and ellagic acid peaks in PEE were shown by an
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After appropriate treatment with PEE, human T24 or
J82 cells were harvested and lysed in lysis buffer [10 mM
Tris (pH 8.0), 0.32 M sucrose, 1% (v/v) Triton X-100,
5 mM EDTA, 2 mM DTT, and 1 mM PMSF]. After de-
termining its protein concentration using Bio-Rad DC
protein assay kit, equal volume of 2× sample buffer
[0.1 M Tris (pH 6.8), 2% SDS, 0.2% β-mercaptoethanol,
10% (v/v) glycerol, and 0.0016% (w/v) bromophenol blue]
was combined with the cytoplasmic extract. Appropriate
amounts of the lysates were separated by electrophoresis
at 100 V with 10% (w/v) sodium dodecyl sulfate (SDS)-
polyacrylamide gels, and further transferred on to a PVDF
membrane (Strategene, La Jolla, CA, USA). After blocking
for 1 hour in 3% (w/v) bovine albumin serum (BSA) at


























































Figure 2 The inhibitory efficacy of PEE on UBUC cells. (A) Human T24
72 h and cell viability was measured by MTT assay as described in Methods. (B
human T24 or J82 cells with 50 μg/ml of PEE for various time durations. (C) Th
carried out by exposing the cells in the presence of the indicated concentrati
independent experiments. All the data were expressed as mean ± standard de
*** denoted P < 0.01 and P < 0.001 respectively as compared to untreated celat 4°C with primary antibodies. The primary antibodies
used in this study were listed in supplementary document.
The membranes were washed and probed with suitable
secondary antibodies for 1 hour at room temperature.
Secondary antibodies binding on the membrane were
detected by chemiluminescence ECL detection system
(Amersham-Pharmacia Biotech Inc., Piscataway, NJ, USA)
using Fujifilm LAS-3000 Luminescent Image Analyzer
(Fujifilm Corporation, Tokyo, Japan). The intensity of each
protein band was quantified by PDQUEST Quantity One
software (Bio-Rad Laboratory, Hercules, CA) and normal-
ized with actin protein expression level.
Statistical analyses
Student’s t-test was used to assess the significance between

















































































or J82 cells were incubated with increasing concentration of PEE for
) Time-dependent response experiments were underwent by treating
e selectivity of PEE was determined by dose-response against E7 cell
ons for 72 h. All the diagrams in Figure 2 were the typical result of three
viation (S.D.) of the mean of four wells performed in triplicate. ** and
l using Student’s t-test.
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Inc., Tulsa, Oklahoma, USA).
Results
The suppressive influences of PEE on UBUC cell proliferation
In this work, fresh pomegranate juice was sequentially
extracted using solvent with increasing polarity as shown
in Figure 1A. There are many well-documented literatures
demonstrating that pomegranate possesses anti-cancer
effectiveness against various tumors. Thus we speculated
that pomegranate might inhibit UBUC. To evaluate our
speculation, PEE was evaluated on T24 and J82 cells for
its inhibitory influences on cell proliferation. T24 or J82
cells were incubated for 72 hours with or without various
concentrations of PEE (5 to 200 μg/ml). The experimental
results in Figure 2 demonstrated that the influence of PEE
could be observed in T24 cells after treatment for 72 hours
with 10 μg/ml and in J82 cells for 72 hours with 50 μg/ml.
The effectiveness was more obvious in T24 cells than
that in J82 cells. However, the suppressive effects of
PEE were more prominent after treatment for 72 hours
with >50 μg/ml both in T24 and J82 cells. After 72 hours,
approximately 80% of T24 or J82 cells were dead after
incubation with 100 μg/ml of PEE. Besides, 50 μg/ml
PFE- exposure to T24 cell for various periods (0 to
72 hours) inhibited cell proliferation. The observation
results suggested that PEE could affect the viability of
UBUC cells.
The inhibitory influence of PEE on cell survival ob-
served in T24 or J82 cells suggested that PEE might
similarly impact normal cells. E7 cells were employed to
examine this likelihood. As indicated in Figure 2C, al-
most all the E7cells survived after 72 hours treatment in
all the PEE concentrations tested. However, PEE couldTable 1 The composition of PEE evaluated by GC/MS





Furyl hydroxymethyl ketone 1.03
3,5-dihydroxy-2-methyl-4H-Pyran-4-one 0.80










aOnly the compounds with identification score (SI) > 90 were listed.impede bladder cancer T24 or J82 cell in a dose-
dependent manner. Thus normal and cancer cell lines
exhibited differential sensitivity to PEE.
In order to get insight into the constituents present in
PEE, PEE was subjected to HPLC and the results were
shown in Figure 1. HPLC results demonstrated that
most compounds in PEE were present in the medium
polar area (retention time from 40 to 90 minutes). A
possible ellagic acid peak and a potential punicalagin
peak appeared in HPLC profile of PEE when compared
to those of pure ellagic acid and pure punicalagin in
Figure 1. These two compounds seem to be the major
ingredients in PEE. Consistent with HPLC results, GC/
MS results showed that furanaldehyde, furanketone and
pryrrolo[1,2-α]pyrazine compounds were present in PEE
(Table 1). However, further investigation was required to
decide whether these compounds were linked to the anti-
cancer activities of PEE.PEE interfered with human T24 cell proliferation by
inducing cell cycle arrest
According to the above results, PEE could invoke an
inhibitory impact on human T24 cell proliferation. To
discover which mechanism was involved in the inhibition
of human T24 cell proliferation, PEE-exposed human
T24 cells were first investigated with cell cycle analysis
using flow cytometry. Cell cycle analyses conducted after
incubation of human T24 cell with a series of increasing
concentration for various durations demonstrated that
PEE arrested human T24 cells in S phase in a dose-and-
time dependent response (Figure 3A). After exposure to
100 μg/ml for 72 hours, 39.5% of the cells were arrested
at the S phase, whereas only 23.7% were at the G2/M
phase and 27.3% at the G1 phase of the cell cycle. Previous
evidences reported that during normal cell cycle cyclin
A- CDK1 (cyclin-dependent kinase 1) complex begins
to form in late S phase and is over-expressed in G2
phase to result in the progression from S phase to G2/
M phase [21,22]. Thus western immunoblotting was car-
ried out to detect the impact of PEE on the expressions of
cyclin A and CDK1 in human T24 cells. The subsequent
findings showed that cyclin A level was increased whereas
CDK1 level was decreased in PEE-treated human T24 cell
(Figure 3), suggesting that PEE evoked S phase arrest in
human T24 cell possibly through the dys-regulation of
cyclin A and CDK1.
In addition, PEE treatment increased G2/M population
as compared to those of the untreated T24 cells. How-
ever, G2/M arrest induced by PEE was not statistically
significant (Additional file 1: Table S1). Western immuno-
blotting indicated that PEE exposure resulted in the
over-expressions of CDC25C, pCDC25 and cyclin B1 in
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(C)
Figure 3 Induction of human T24 cell cycle arrest by PEE. Human T24 cells were incubated with 50 or 100 μg/ml of PEE for the indicated
time periods and cell cycle analyses were determined by flow cytometry as described in section 2. The representative diagram was shown in
(A), and the mean ± S.D. of three independent experiments was indicated in the right panel. Human T24 cells were treated with 50 or 100 μg/ml
of PEE for different time durations and cyclin A as well as CDK1 in cell lysates were detected by western blotting with the antibodies against
cyclin A (B) and CDK1 (C) respectively as described in section 2. The blot in each diagram was the representative result of three independent
experiments and the densitometer-intensity data (mean ± S.D.) were shown under each blot. *, ** and *** represented P < 0.05, P < 0.01 and
P < 0.001 respectively as compared to untreated cell using Student’s t-test.
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G2/M arrest.
PEE dampened human T24 cell proliferation by evoking
the apoptosis via mitochondrial pathway as well as death
receptor signaling
In addition to cell cycle arrest, we also explored the like-
lihood that the inhibitory effects of PEE on human T24
cell proliferation might be attributed to the apoptosis.The data of cell cycle analyses indicated that PEE exposure
could induce the formation of hypodiploid subG1 peak
in a dose-and-time dependent response as compared to
those of the control, implicating that PEE could cause
the DNA fragmentation in human T24 cells, although
the percentage of subG1 population in the cell profile
was low (< 2.3%). The results of annexin V/PI staining
indicated that after incubation with PEE in a dose-and-time
dependent manner it could provoke phosphatidylserine
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sign of apoptosis that leads to the subsequent membrane
leakage (late apoptotic cell) and thus increases the per-
centage of early and late apoptotic cells (Figure 4).
Although the aforementioned results showed that PEE
might induce the apoptosis in human T24 cell, cytometric
analysis cannot decipher whether PEE results in the apop-
tosis by death receptor signaling, mitochondrial damage
pathway or ER stress. In order to define the molecular
mechanism by which PEE invoked the apoptosis, western
immunoblotting was conducted to examine the processing
and activation of caspase-3 which is considered to play a
central role in both mitochondrial damage and death
receptor signaling, and can be activated by caspase-8 in
death receptor signaling and by caspase-9 in mitochon-
drial damage. As shown in Figure 5A, the amount of
pro-caspase-3 decreased in a time-dependent response,
implicating that caspase-3 was activated and the apoptosis
might be triggered by mitochondrial damage or death
receptor signaling. To reinforce the observation of PEE-
induced apoptosis via activation of pro-caspase-3, PEE-
administrated T24 cell was incubated with caspase-3
inhibitor Z-DEVD-FMK. Significantly reduced numbers
of early apoptotic T24 cells present in inhibitor/PEE
treatment of annexin V/PI staining experiments showed
that Z-DEVD-FMK could antagonize the apoptotic effects
of PEE on human T24 cell as compared to those of sole24 hr
48 hr
72 hr
50 µg/ml 100 µgControl
Figure 4 PEE-provoked human T24 cell apoptosis. Apoptotic effect wa
for the indicated time periods and the effect was measured by the annexin
posted in (A) and the mean ± S.D. of three independent experiments wasPEE exposure (Figure 5B). Similarly pro-caspase-3 was
activated in PEE-treated J82 cell in a dose-and-time relied
response (Figure 5A).
To further uncover the apoptotic mechanism mediated
by PEE, the activation of caspase-8 and -9 in PEE-
exposed human T24 cells were examined by western
immunoblotting. The results in Figure 5C and 5D demon-
strated that the levels of pro-caspase-9 and -8 dwindled
temporally in 50 μg/ml and 100 μg/ml PEE-administrated
human T24 cells whereas activated caspase-9 amount
increased, implying that PEE-induced human T24 cell
apoptosis might be attributed to the mitochondrial dam-
age pathway and death receptor signaling. Backing up the
involvement of mitochondrial damage pathway in PEE-
provoked apoptosis, further experimental results found
that Bcl-2 level decreased while Bax amount increased
(Figure 5E). To confirm death receptor pathway was acti-
vated in PEE-treated T24 cell, western immunblotting
with DR4 and DR5 antibodies was conducted and showed
that DR4 and DR5 was up-regulated in PEE-incubated
T24 cells, implying that death receptor was involved in
the apoptosis induced by PEE in T24 cells (Figure 5F).
PEE caused endoplasmic reticulum (ER) stress to induce
the apoptosis in T24 cell
The above findings demonstrated that PEE caused human



















































































s observed by treating human T24 cells with 50 or 100 μg/ml of PEE
V/PI staining as described in section 2. The representative data was
demonstrated in (B).
Figure 5 PEE-evoked human T24 cell apoptosis via the mitochondrial pathway and death receptor pathway. Human T24 or J82 cells
were treated with 50 or 100 μg/ml of PEE for different time durations. Various effector proteins involved in apoptosis were detected by western
blotting with the antibodies against procaspase-3 (A), procaspase-9 (C), procaspase-8 (D), Bax/BcL-2 (E), DR4 and DR5 (F) respectively as described in
section 2. T24 cells were investigated in all panels except panel A as indicated. The blot in each diagram was the typical result of three independent
experiments except pro-caspase-3 examination in J82 cell (one experiment) and DR4 as well as DR5 detection (two independent experiments) in T24
cells. The densitometer-intensity data (mean ± S.D.) were shown under each blot. (B) For the counteract study, human T24 cells were incubated with
2 μM of caspase-3 inhibitor Z-DEVD-FMK for 4 hours and then 100 μg/ml of PEE was incorporated with the inhibitor-pretreated cells for 48 hours. After
incubation, the cells were collected for annexin V/PI analyses.
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PEE exposure could also result in ER stress, and thus
cell apoptosis in human T24 cell. Hence the processing
and activation of pro-caspase-12, which is regarded as
an essential effector in ER stress, was examined by
western immunoblotting. The follow-up discovery showed
that pro-caspase-12 level was reduced while cleaved
pro-caspase-12 (activated form) amount increased in
PEE-exposed T24 cells in a temporal response (Figure 6A),
implicating that PEE might provoke an ER stress in
human T24 cell. To further clarify the impacts of PEE
on ER stress, western immunoblotting was conducted
to detect CHOP and Bip, the ER stress markers whose
over-expression will initiate ER stress. The follow-up
results illustrated that both CHOP and Bip levels were
increased in PEE-treated human T24 cells (Figure 6Band 6C), reinforcing that PEE treatment caused ER stress
in human T24 cell. Previous findings implicated that
during chemically induced ER stress, valosin-containing
protein (VCP) triggers processing and activation of pro-
caspase-9 and -12 [23]. This investigation found that PEE
exposure augmented the VCP expression in T24 cells
using western immunoblotting (Figure 6D), implying
that PEE treatment might evoke ER stress in T24 cells
through VCP de-regulation.
Discussion
Pomegranate has been illustrated to possess anti-carcino-
genic properties that may suppress various cancers. Many
research applications have been made to determine the
chemopreventive effects of pomegranate on lung cancer
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(D)
(A)
Figure 6 PEE-evoked ER stress in human T24 cell. Human T24 cells were treated with 50 or 100 μg/ml of PEE for different time durations.
Various effector proteins participating in ER stress were detected by western blotting with the antibodies against procaspase-12 (A), CHOP (B),
BiP (C) and VCP (D) respectively as described in section 2. The blot in each diagram was the representative result of three independent experiments
and the densitometer-intensity data (mean ± S.D.) were shown under each blot.
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inhibit prostate cancer and lung cancer both in vitro and
in vivo [10-15]. Above that, following primary treatment,
with daily consumption of 8 ounces of pomegranate fruit
juice, prostate cancer patients can extensively lengthen
prostate-specific antigen doubling time [16]. Thus pom-
egranate may be a potential chemopreventive source
against UBUC progression and recurrence based upon
previous evidences. The incidence of bladder cancer in
southwestern coast of Taiwan, where blackfoot disease
is endemic, is unusually high. Epidemiological studies
have established a link between arsenic and bladder
cancer [24]. Since there is no eveidence-based literature
showing the inhibitory efficacy of pomegranate to UBUC,
and high incidence as well as frequent recurrence of UBUC
still prevails in southwestern Taiwan, this study was
intended to examine if pomegranate could impede UBUC
growth. The results of this study hope to provide the basisfor future development in adopting local pomegranate
as a chemopreventive source against UBUC in Taiwan.
In this study we found that PEE treatment could inhibit
UBUC T24 and J82 cell proliferation in a time-and-dose
dependent response. Cell cycle analyses demonstrated that
PEE exposure caused S-phase arrest in human T24
cells and de-regulation of cyclin A as well as CDK1, the
complex of which is essential for S to G2/M transition.
Similar results were reported by Shi et al. (2003) [25]
that the treatment of prostate cancer cell with BBSKE, a
novel organoselenium compound, results in S-phase arrest
and increase in the protein levels of cyclin A, cyclin E, and
p21, but decrease in the levels of cyclin B1, cyclin D1,
and CDK4 [25]. Furthermore, BBSKE augments Bax/
Bcl-2 ratio, and thus induces apoptosis. In contrast,
PFE (acetone extract of pomegranate juice) incubation
results in G1 phase arrest in prostate cancer and lung
cancer cells [11-13].
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http://www.biomedcentral.com/1472-6882/13/364Besides cell cycle arrest, the inhibitory activity of PEE
toward UBUC cells might be attributed to apoptosis. MTT
results demonstrated that PEE exhibited the stronger
inhibitory effect on T24 cell than J82 cell. Moreover,
both of T24 and J82 cells belong to high grade UBUC
cells. Thus we chose T24 cells for further exploration
of the molecular pathway involved in apoptosis. The
results of annexin V/PI staining demonstrated that PEE
treatment could evoke T24 cell apoptosis in a dose-and-
time dependent manner. The investigation of processing
and activation of various proapoptotic caspases revealed
that PEE treatment activated pro-capspase-3, -8 and -9 in
T24 cells, implying that mitochondrial pathway and death
receptor pathway might be involved in initiating apoptosis.
Furthermore we found that pro-caspase-12 level signifi-
cantly reduced while the amount of activated caspase-12
prominently increased in PEE-exposed T24 cells in a
temporal response as compared to those of pro-caspase-
3, -8 and -9, indicating that ER stress might be the domin-
ant pathway to evoke apoptosis although mitochondrial
pathway and death receptor pathway also could induce
apoptosis in T24 cells. Over-expression of ER stress
markers, CHOP and BiP, further backed up the observation
of PEE-induced ER stress. Previous reports demonstrated
that when ER stress was induced by chemicals, VCP might
become a key component of a large ER-associated complex
which triggered processing and activation of pro-caspase-9
and -12 [23]. The aforementioned phenomenon implicated
that PEE exposure might provoke ER stress in human T24
cells followed by VCP over-expression to trigger the activa-
tion of pro-caspase-9 and -12. Besides, pro-caspase-3 was
activated in a dose-and-time dependent manner in PEE-
treated J82 cell, indicating that similar apoptotic mechan-
ism might be provoked by PEE exposure.
In resemblance to our findings, the examination of PFE
(acetone extract) reported by Malik et al. (2005) found
that PFE treatment to prostate cancer and lung cancer
cells could induce G1 phase arrest and provoke prostate
cancer cell apoptosis by dys-regulation of both cyclins and
CDKs and down-regulation of anti-apoptotic Bcl-XL and
Bcl-2 [13]. However, few evidences supported that PFE
could induce cell apoptosis in prostate cancer and lung
cancer cells. This study provided extensive findings which
showed that PEE administration could evoke UBUC
cell apoptosis.
Conclusions
In conclusion, PEE treatment could suppress UBUC
cell and might trigger the apoptosis in bladder cancer
cell through death receptor signaling and mitochondrial
damage pathway. More importantly PEE exposure could
provoke intensive activation of ER stress which might
be the cardinal apoptotic mechanism of PEE-induced
inhibition of bladder cancer cell. The analytical resultsof this study help to provide insight into the molecular
mechanism of inducing bladder cancer cell apoptosis
by pomegranate and to develop novel mechanism-based
chemopreventive strategy for bladder cancer.
Additional files
Additional file 1: Supplementary methods, supplementary tables
and supplementary figure legends.
Additional file 2: Supplementary figures.
Competing interests
The authors declare no financial or commercial conflict of interest.
Authors’ contributions
MHL and LHC performed most of western immunoblotting experiments.
LCH carried out most of apoptosis assays. GIL identified pomegranate and
deposited the plant. STL participated in the project design, contributed to
the data interpretation and wrote the initial drafts of the manuscript. TFW
carried out the preparation of PFE and contributed to the conception and
design of the entire study, the data interpretation, the initial draft and final
editing of the manuscript. All authors have read and approved the
manuscript for publication.
Acknowledgements
The authors would like to thank the National Science Council of Taiwan for
financially supporting this research under Contract No. NSC 99-2313-B-218-
001-MY3 and 101-2632-B-218-001-MY3. We also would like to thank Miss
Shu-Ju Chen for editing the manuscript.
Author details
1Department of Biotechnology, Southern Taiwan University of Science and
Technology, Nan-Tai Street, Tainan, Yung-Kung District 710, Taiwan.
2Department of Life Sciences, University Road, National Cheng Kung
University, Tainan 701, Taiwan.
Received: 2 July 2013 Accepted: 11 December 2013
Published: 21 December 2013
References
1. Block G, Patterson B, Subar A: Fruit, vegetables and cancer prevention: a
review of the epidemiological evidence. Nutr Canc 1992, 18:1–29.
2. Mukhtar H, Ahmad N: Cancer chemoprevention: future holds in multiple
agents. Toxicol Appl Pharmacol 1999, 158:207–210.
3. Parnes HL, Thompson IM, Ford LG: Prevention of hormone-related cancers:
prostate cancer. J Clin Oncol 2005, 23:368–377.
4. Saleem M, Adhami VM, Siddiqui IA, Mukhtar H: Tea beverage in
chemoprevention of prostate cancer: a mini-review. Nutr Canc 2003,
47:13–23.
5. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev
Canc 2003, 3:768–780.
6. Langley P: Why a pomegranate? BMJ 2000, 321:1153–1154.
7. Cerda B, Ceron JJ, Tomas-Barberan FA, Espin JC: Repeated oral administration
of high doses of pomegranate ellagitannin punicalagin to rats for 37 days
is not toxic. J Agri Food Chem 2003, 51:3493–3501.
8. Cerda B, Llorach R, Ceron JJ, Espin JC, Tomas-Barberan FA: Evaluation of the
bioavailability and metabolism in the rat of punicalagin, an antioxidant
polyphenol from pomegranate juice. Eur J Nutr 2003, 42:18–28.
9. Gil MI, Tomas-Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA: Antioxidant
activity of pomegranate juice and its relationship with phenolic composition
and processing. J Agri Food Chem 2000, 48:4581–4589.
10. Hong MY, Seeram NP, Heber D: Pomegranate polyphenols downregulate
expression of androgen synthesizing genes in human prostate cancer cells
overexpressing the androgen receptor. J Nutr Biochem 2008, 19:848–855.
11. Khan N, Hadi N, Afaq F, Syed DN, Kweon MH, Mukhtar H: Pomegranate
fruit extract inhibits prosurvival pathways in human A549 lung
carcinoma cells and tumor growth in athymic nude mice.
Carcinogenesis 2007, 28:163–173.
Lee et al. BMC Complementary and Alternative Medicine 2013, 13:364 Page 11 of 11
http://www.biomedcentral.com/1472-6882/13/36412. Khan N, Afaq F, Kweon MH, Kim K, Mukhtar H: Oral consumption of
pomegranate fruit extract inhibits growth and progression of primary
lung tumors in mice. Canc Res 2007, 67:3475–3482.
13. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H: Pomegranate
fruit juice for chemoprevention and chemotherapy of prostate cancer.
Proc Natl Acad Sci U S A 2005, 102:14813–14818.
14. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A,
Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A: Pomegranate extract
inhibits androgen-independent prostate cancer growth through a nuclear
factor-kappaB-dependent mechanism. Mol Canc Ther 2008, 7:2662–2671.
15. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A,
Rettig MB, Aronson WJ, Pantuck AJ, Heber D: Ellagitannin-rich pomegranate
extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J
Oncol 2008, 32:475–480.
16. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ,
Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L,
Belldegrun A: Phase II study of pomegranate juice for men with rising
prostate-specific antigen following surgery or radiation for prostate cancer.
Clin Canc Res 2006, 12:4018–4026.
17. Bane BL, Rao JY, Hemstreet GP: Pathology and staging of bladder cancer.
Semin Oncol 1996, 23:546–570.
18. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ,
Skinner DG, Cote RJ: Prognostic markers in bladder cancer: a
contemporary review of the literature. J Urol 1998, 160:645–659.
19. Zieger K, Wolf H, Olsen PR, Hojgaard K: Long-term follow-up of noninvasive
bladder tumours (stage Ta): recurrence and progression. BJU Int 2000,
85:824–828.
20. Chen SH, Wang YW, Hsu JL, Chang HY, Wang CY, Shen PT, Chiang CW,
Chuang JJ, Tsai HW, Gu PW, Chang FC, Liu HS, Chow NH: Nucleophosmin
in the pathogenesis of arsenic-related bladder carcinogenesis revealed
by quantitative proteomics. Toxicol Appl Pharmacol 2010, 242:26–35.
21. Bendris N, Lemmers B, Blanchard JM, Arsic N: Cyclin A2 mutagenesis
analysis: a new insight into CDK activation and cellular localization
requirements. PLoS ONE 2011, 6:e22879.
22. Yam CH, Fung TK, Poon RY: Cyclin A in cell cycle control and cancer.
Cell Mol Life Sci 2002, 59:1317–1326.
23. Braun RJ, Zischka H: Mechanisms of Cdc48/VCP-mediated cell death:
from yeast apoptosis to human disease. Biochim Biophys Acta 2008,
1783:1418–1435.
24. Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, Lee MS, Christiani DC:
Arsenic methylation and bladder cancer risk in Taiwan. Canc Causes Contr
2003, 14:303–310.
25. Shi C, Yu L, Yang F, Yan J, Zeng H: A novel organoselenium compound
induces cell cycle arrest and apoptosis in prostate cancer cell lines.
Biochem Biophys Res Commun 2003, 2003(309):578–583.
doi:10.1186/1472-6882-13-364
Cite this article as: Lee et al.: Suppression of urinary bladder urothelial
carcinoma cell by the ethanol extract of pomegranate fruit through cell
cycle arrest and apoptosis. BMC Complementary and Alternative Medicine
2013 13:364.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
